. In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries.
recombinant adenoviral vectors; vasodilatation; gene transfer; rabbit ERYTHROPOIETIN (Epo) was originally described as a regulator of erythropoiesis (26) . However, the biological effects of Epo are not restricted to erythroid precursor cells. Epo can also affect the functions of endothelial, vascular smooth muscle, myocardial, mesangial, and neuronal cells (4 -6, 19, 32, 34, 45) . Epo modulates a broad array of cellular processes that include progenitor stem cell development, cellular integrity, and angiogenesis (31) .
Recently, several studies have demonstrated a significant neuroprotective effect of Epo and its nonhematopoietic derivatives (9, 17, 20, 27) , and a proof of concept clinical trial demonstrated beneficial effects of Epo in patients with an acute stroke (16) . The concentration of Epo used to demonstrate therapeutic efficacy of Epo in experimental models of neurological disorders as well as in patients with acute stroke is about 500-to 1,000-fold higher than the circulating levels of Epo (16, 28) . However, the effect of such high circulating, but therapeutically effective, levels of Epo on normal cerebral vasculature has not been studied.
Epo is reported to increase endothelial nitric oxide (NO) synthase (eNOS) expression and NO production in cultured endothelial cells (7) . Administration of Epo has also been reported to increase eNOS expression in vivo in rats (23) . However, long-term administration of Epo in patients is associated with hypertension (18, 24, 37) , in part, mediated by either increased intracellular calcium in smooth muscle cells (43) or increased endothelin production (10, 11) . In addition, Epo can impair endothelium-dependent vasodilatation in humans, probably through a cyclooxygenase-dependent mechanism (44) . Hence, divergent effects of Epo on the vasculature have been reported to date. In a recent study, we observed that Epo increased the phosphorylation of eNOS and reversed cerebral vasospasm rabbits subjected to subarachnoid hemorrhage (39) . From these the findings, we hypothesized that in the cerebral vasculature, Epo increases the expression and activation of eNOS and augments vasodilatation.
MATERIALS AND METHODS

Animals.
Male New Zealand White rabbits (2-3 kg) were used for experiments. Rabbits were anesthetized with an intramuscular injection composed of ketamine (35 mg/kg), xylazine (5 mg/kg), and acepromazine (2.3 mg/kg). Animals were anesthetized and euthanized on day 2 with intravenous pentobarbital sodium (Sleepaway, 260 mg/kg, Fort Dodge Animal Health). All procedures were approved by the Institutional Animal Care and Use Committee. Biological parameters measured in animals included heart rate, hematocrit, hemoglobin, erythrocyte count, and white blood cell count.
Adenoviral vectors and gene transfer. Replication-incompetent adenovirus encoding the human erythropoietin (AdEpo) gene and Escherichia coli ␤-galactosidase (AdLacZ; vector-control in this study) were obtained from the Vector Core of the University of Pittsburgh. Control rabbits or arteries refer to those not exposed to vector. Cerebrospinal fluid (CSF, 300 l) was aspirated and mixed with 50 l vector [10 9 plaque-forming units (pfu)] or vehicle and injected aseptically by using a 25-gauge needle into the cisterna magna (25, 36) . The transduction titer of 10 9 pfu/rabbit was chosen based on previous in vivo gene transfer studies (12, 25) . After injection, animals were maintained in a head-down position for 30 min before transfer to postanesthesia recovery.
Measurement of EPO levels. Epo levels in the CSF and plasma were measured by a two-site chemiluminescence immunoassay using the Nichols Erythropoietin Immunoassay kit (Nichols Institute Diagnostics, San Clemente, CA) as described elsewhere (39) .
Western blot analysis. Soluble proteins were extracted by mincing and homogenizing tissues in lysis buffer as described earlier (39) . Briefly, 50 g protein were separated by electrophoresis and transferred onto nitrocellulose membrane. Ponceau S staining of the membrane was performed to confirm equal loading subsequent to transfer. Blots were incubated with monoclonal antibody (1:500 dilution) against inducible NOS, phosphorylated S1177-eNOS (BD Transduction), actin (Santa Cruz), Akt and phosphorylated S473-Akt (Cell Signaling), heme oxygenase-1 (HO-1, Stressgen), and polyclonal antibodies to eNOS (BD Biosciences), Epo, and EpoR (Santa Cruz). Bands were visualized by enhanced chemiluminescence (Amersham Pharmacia).
Analysis of vascular reactivity. Ring segments (ϳ3 mm long) were connected to an isometric force-displacement transducer (Grass FT03; Grass Instrument) and suspended in an organ chamber filled with 25 ml of Krebs solution (in mmol/l: 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 0.026 calcium-ethylenediaminetetracetic acid, and 11.1 glucose, 37°C, pH 7.4) aerated with 94% O2-6% CO2 (13). Isometric force was recorded continuously. The rings were gradually stretched and allowed to stabilize at a resting force of 500 mg for 45 min. Rabbit basilar arteries were contracted with histamine (3 ϫ 10 Ϫ7 to 1 ϫ 10 Ϫ6 mol/l) (21, 34, 38) before the cumulative addition of either acetylcholine (10 Ϫ9 to 10 Ϫ5 mol/l) or 2-(N,N-diethylamino)diazenolate-2-oxide sodium salt (DEA-NONOate; 10 Ϫ9 to 10 Ϫ5 mol/l) to obtain the relaxation responses. Measurement of cGMP and cAMP. Rabbit basilar arteries were incubated in minimum essential medium in a CO2 incubator at 37°C for 30 min in 3-isobutyl-1-methylxanthine (IBMX, 10 Ϫ3 mol/l; Sigma) to inhibit the degradation of cyclic nucleotides by phosphodiesterases. The rings were then removed from the medium and quickly frozen in liquid nitrogen. After homogenization, cGMP and cAMP levels were measured by cGMP and cAMP radioimmunoassay kits, respectively (Amersham) (3). Protein assay was conducted by DC Protein Assay kit (Bio-Rad).
Drugs. DEA-NONOate was obtained from Cayman Chemical. All other drugs used in the study were obtained from Sigma. Concentrations of all drugs are expressed as the final moles per liter in the organ chambers.
Statistical analysis. Results of the study are expressed as means Ϯ SE of the number of rabbits in each group (n) used in each experimental group. Relaxations are expressed as percentage of maximal relaxations induced by 3 ϫ 10 Ϫ4 mol/l papaverine. cGMP values were analyzed by unpaired Student's t-test. Densitometric value comparisons across different groups were assessed by one-way ANOVA followed by pairwise comparisons. Differences among relaxation values across concentration-response curves were analyzed by twoway ANOVA followed by pairwise comparisons. Multiple comparisons adjustment was performed by Bonferroni method. A P value Ͻ0.05 was considered statistically significant.
RESULTS
Physiological parameters.
In vivo gene delivery did not affect the counts of red blood cells (RBCs), white blood cells (WBCs), hemoglobin, or hematocrit after 2 days (Table 1 ). The CSF and plasma levels of Epo were significantly increased in the AdEpo-transduced group compared with either control or AdLacZ-transduced rabbits (Table 1) . We do not have an explanation for the 10-fold higher levels of Epo detected in the CSF compared with the levels in plasma under basal conditions. We speculate that this observation could be attributable to the nonspecific binding of the human antibodies to proteins present in the rabbit CSF.
Gene transfer of erythropoietin to basilar arteries. Subsequent to gene transfer, as shown by Western blot analysis, protein expression of Epo and EpoR were detected or increased respectively only in AdEpo-transduced basilar arteries (Fig. 1) .
Effect of Epo on vasomotor function of rabbit basilar arteries. Concentration-dependent contractions to histamine (10
Ϫ9
to 10 Ϫ5 mol/l) were significantly reduced in AdEpo-transduced basilar arteries (Fig. 2) . Endothelium-dependent relaxations to acetylcholine were significantly augmented in basilar arteries transduced with AdEpo compared with AdLacZ-transduced basilar arteries (Fig. 3A) . Endothelium-independent relaxations to a NO donor DEA-NONOate (10 Ϫ9 to 10 Ϫ5 mol/l) were not different among control, AdLacZ-, or AdEpo-transduced basilar arteries (Fig. 3B) .
In AdEpo-transduced arteries, the expressions of eNOS (Fig.  4A ) and phosphorylated S1177-eNOS (Fig. 4B) were significantly elevated compared with AdLacZ-transduced arteries, whereas the expressions of iNOS (Fig. 4C) and HO-1 (Fig. 4D) remained unchanged. Furthermore, the expression of phosphorylated S473-Akt was significantly increased in AdEpotransduced arteries, whereas the expression of Akt remained unchanged (Fig. 5) .
Gene transfer of AdEpo significantly elevated the basal levels of cGMP compared with rabbits transduced with Ad- LacZ (Fig. 6A ). This effect was selective for cGMP because levels of cAMP were not affected by Epo (Fig. 6B) .
DISCUSSION
This is the first in vivo study to examine the effects of recombinant Epo on normal cerebral arteries. Our study reports several novel findings. In cerebral arteries treated with recombinant Epo, contractile responses to histamine were attenuated, whereas endothelium-dependent relaxations to acetylcholine were significantly augmented. Furthermore, perivascular gene delivery of recombinant Epo increases the expression of eNOS, phosphorylated S1177-eNOS, and phosphorylated S473-Akt and elevates cGMP in the vasculature, thereby suggesting that exposure of cerebral arteries to recombinant Epo augments endothelial production of NO.
In the present study, experiments were performed on the basilar artery primarily because of its proximity to the site of gene delivery, i.e., cisterna magna. In a series of previous studies, we demonstrated that intracisternal gene delivery resulted in expression of recombinant protein in adventitial fibroblasts of cerebral arteries (3, 12, 13, 25, 36, 42) . In the present study, successful gene transfer was confirmed by the increased levels of Epo in CSF and by the detection of Epo in the AdEpo-transduced basilar arteries. We also detected an increase in circulating levels of Epo. This observation could be explained by the crossing of Epo from CSF into the systemic circulation. Less likely, but another possible explanation involves transduction of peripheral tissues by recombinant AdEpo translocated from the CSF to systemic circulation. We want to point that the circulating levels of Epo were comparable to the concentration detected in patients treated with intravenous injections of Epo during an acute stroke (16) . To the best of our knowledge, this is the first report to demonstrate the vascular effect of Epo at concentrations, which in clinical trials, exert beneficial effects in patients with an acute stroke. The increased expression of EpoR in Epo-transduced blood vessels suggests that in cerebral arteries, EpoR expression is regulated by Epo, in part, by reduced EpoR degradation as proposed by Martinez-Estrada and colleagues (33) . Our results are also in agreement with previous reports on EpoR regulation in cultured endothelial cells and neurons (7, 14) and provide an additional insight into the vascular protective and neuroprotective mechanism(s) of recombinant Epo.
In an earlier study, we reported that the cerebral vascular protective effect of recombinant Epo during subarachnoid hemorrhage-induced cerebral vasospasm is mediated, in part, by augmentation of endothelium-dependent relaxations, increased phosphorylation of eNOS, and elevation of cGMP levels in the cerebral arteries (39) . On the basis of these observations, we first examined the effect of Epo on contractions and relaxations in AdEpo-transduced arteries. In the present study, we expanded our previous findings and demonstrated that in normal cerebral arteries, expression of recombinant Epo attenuates contractile responses to histamine. The exact mechanism responsible for reduced contractions to histamine is unknown but may include increased basal production of NO or activation of eNOS by histamine (29, 41) . Furthermore, we observed augmentation of endothelium-dependent relaxations to acetylcholine, whereas the smooth muscle reactivity to NO remained unaffected, suggesting that the endothelium is major target for cerebral vascular effect of Epo.
Recombinant human Epo is known to exert vasoconstrictor effects on isolated renal and mesenteric resistance vessels (22) , and high concentrations of Epo have been shown to induce contractions of rat mesangial and aortic smooth muscle cells (34) . In cultured endothelial cells, recombinant Epo may reduce expression of eNOS, whereas in vascular smooth muscle cells Epo raises the cytosolic calcium content of vascular smooth muscle cells by stimulation of protein kinase C and phospholipase C␥1 (2, 43, 46) . However, in these studies, the concentrations of Epo used (20 -250 U/ml) greatly exceeded concentrations observed in plasma after adenoviral-mediated gene transfer of recombinant Epo in our study (ϳ5 U/ml; Table 1 ). Our findings demonstrate that in cerebral arteries, recombinant Epo increased the phosphorylation of Akt and eNOS, resulting in augmentation of endothelium-dependent relaxation to acetylcholine. Indeed, endothelium-dependent relaxations to acetylcholine in rabbit basilar arteries are predominantly mediated by NO (30, 40) . The lack of potentiation of relaxations by an endothelium-independent vasodilator DEA-NONOate suggests that the effect of Epo is selective for endothelial cells.
High basal levels of cGMP detected in Epo-transduced arteries most likely reflect high enzymatic activity of eNOS and increased NO production, consistent with Epo-induced increase in expression of eNOS. The protein expressions of iNOS and HO-1 remained unchanged in Epo-transduced arteries, reinforcing our conclusion that the effect of Epo is mediated by enhanced endothelial NO production in cerebral arteries. This is in line with the results obtained on transgenic mice overexpressing human Epo (38) , wherein increased eNOS synthase expression, enhanced NO-mediated endothelium-dependent relaxation, and elevated circulating and vascular tissue NO were observed. In contrast to Epo-transgenic mice, the contribution of shear stress to stimulation of eNOS activity (8, 15) in cerebral arteries after exposure to Epo is unlikely, because we did not observe an increase in RBC number 2 days after adenoviral gene transfer.
As the clinical investigation into the application of recombinant Epo in stroke is gaining impetus, the multiple paracrine/ autocrine functions of this hematopoietic hormone are emerging. In addition to neuroprotection, Epo exerts protection against ischemic injury in the heart and induces angiogenesis in vivo. Our results provide the first in vivo evidence that recombinant Epo has a direct action on the endothelium and increases NO bioavailability by upregulation of eNOS in cerebral circulation. The findings of the present study offer an insight into the potential mechanism(s) underlying the vascular protection by Epo.
